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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Abnormal 
glycosylation of  
IgA in cirrhosis
Deposition of IgA in the glomeruli in 
some patients with alcoholic cirrho-
sis has been well recognized. It is now 
clear that, in IgA nephropathy, the IgA 
molecules lack the terminal galac-
tose and sialic acid, which are added 
to N-acetylgalactosamine. These sugar 
abnormalities likely play a very signifi-
cant role in the formation of deposits on 
the mesangial cells. In IgA nephropathy, 
this abnormally glycosylated IgA also 
causes proliferation of mesangial cells 
in vitro, suggesting that it might play a 
role in pathogenesis. Tissandié et al. 
show that patients with advanced alco-
holic cirrhosis have the same anomaly in 
their IgA molecules. The IgA is shown 
to bind to human mesangial cells but 
does not seem to induce proliferation. 
The abnormally glycosylated IgA in IgA 
nephropathy has recently been shown 
to be inherited in IgA nephro pathy. The 
paper by Tissandié et al. suggests that 
environmental influences might also 
cause this, but more work needs to be 
done to rule out inherited susceptibili-
ties in the patients with cirrhosis who 
develop IgA glycosylation anomalies. 
See page 1352.
Sickle-cell trait  
and progression of 
renal disease
Sickle-cell disease is associated with 
chronic kidney disease (CKD) and pro-
gression to renal failure, and the associa-
tion is likely to be causative. Homozygous 
mutations result in sickling, especially in 
the medulla, with consequent occlusion of 
the vasa recta and tubulointerstitial dam-
age. Hicks et al. addressed the question of 
whether the heterozygotes with sickle-cell 
trait are also associated with renal disease 
or progression of renal disease caused 
by another condition. They used a large 
database of African Americans and found 
that the trait was present in about 7–8% 
of the population. They also tested for the 
presence of variants of APOL1 and MYH9 
that are known to be associated with renal 
disease. There were close to 1000 patients 
with type 2 diabetes in the cohort stud-
ied. While it is obvious that these con-
ditions are all associated with a risk of 
end-stage renal disease (ESRD), there did 
not appear to be an influence of the pres-
ence of sickle-cell trait on the presence of 
CKD or ESRD in any of these conditions. 
Hence, the message of this article to the 
large population of subjects with the trait 
is that the presence of this heterozygous 
mutation does not add to their risk of 
renal disease. See page 1339.
Objective and 
perceived knowledge 
of CKD by patients
Communications between patients and 
physicians are in a sorry state, especially 
in the case of chronic diseases such as 
CKD. As they report in this issue, Wright 
Nunes et al. quantified this dismal state 
using formal testing of more than 300 
patients with CKD. Shockingly, almost 
three-quarters of the patients did not have 
a clear understanding of their medications 
and how or whether they could help their 
kidney function. An interesting aspect 
of this study is the comparison between 
objective knowledge, what patients actu-
ally know, and their perceived knowledge, 
what they think they know. This study, full 
of the statistical analysis that sometimes 
can hide the basic piece of information, 
has a simple message: patients need edu-
cation regarding their disease, as this will 
increase their involvement in the way the 
disease is managed. An added benefit is 
the likely increase in patients’ satisfaction 
with the care delivered by their nephrol-
ogists when their objective knowledge 
increases. See page 1344.
